AOD-9604 is a modified human-growth-hormone fragment. FDA's 2024 review describes limited clinical-study summaries and reports that a 502-person obesity trial did not show a significant primary-endpoint difference from placebo.

Insufficient evidence. Review the research and limitations before relying on this record.

AOD-9604 is a peptide corresponding to the C-terminal fragment of human growth hormone, residues 177-191, designed to reproduce the lipolytic action of growth hormone without its diabetogenic effects. It does not act directly through the growth hormone receptor, and although both hGH and AOD-9604 increase beta-3 adrenergic receptor expression, the lipolytic action is not mediated directly through that receptor either. The mechanism is therefore not fully resolved.

A half-life of about 3 minutes has been reported in pigs; no human value is established. A metabolite (CRSVEGSCG) showed greater serum stability than the parent compound.

AOD-9604 was tested at scale and did not work. FDA's review describes a 502-person obesity trial that showed no significant difference from placebo on its primary endpoint. Development did not proceed to approval in any jurisdiction. The route also matters: the oral formulation later pursued as a food ingredient is not the injectable use it is marketed for.

Beyond the failed obesity programme, no controlled human adverse-effect dataset is curated. AOD-9604 is prohibited by the World Anti-Doping Agency. FDA removed it from the Category 2 interim compounding list in September 2024 after the nomination was withdrawn - a procedural change rather than a safety finding. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.

FDA notes incomplete study reporting, no FDA-approved AOD-9604 products, and insufficient evidence for obesity treatment. This does not support use for any other goal, route, formulation, protocol, or dose.